XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)
$ in Millions
 1 Months Ended 9 Months Ended
May 31, 2021
USD ($)
Oct. 01, 2021
USD ($)
target
Asset Acquisition [Line Items]    
Upfront payment   $ 28.0
Collaborative arrangement, maximum aggregate development milestone payments   98.0
Collaborative arrangement, maximum aggregate regulatory milestone payments   229.0
Collaborative arrangement, maximum aggregate commercial milestone payments   802.5
Collaborative arrangement, rights and obligations, maximum aggregate exclusivity payment   $ 15.0
Number of additional oncology targets | target   20
Collaborative arrangement, rights and obligations, maximum aggregate research program funding   $ 30.0
Collaborative arrangement, rights and obligations, research program funding payments, term   3 years
Collaborative arrangement, rights and obligations, aggregate research program funding payments, first installment   $ 5.0
collaborative arrangement, rights and obligations, aggregate research program funding payments, second installment   2.5
Collaborative arrangements, rights and obligations, option exercise payment   $ 3.0
Collaborative Agreement With GamaMabs Pharma SA    
Asset Acquisition [Line Items]    
Payments to acquire assets $ 5.0  
Payment upon closing of transaction 9.0  
Asset acquisition, maximum aggregate development milestone payments 42.0  
Asset acquisition, maximum aggregate regulatory milestone payments $ 22.5